Grufity logoGrufity logo
StocksFundsSearch FilingsAPI

Viatris Inc Stock Research

VTRS

9.62USD-0.10(-1.03%)Delayedas of 27 Sep 2023, 11:20 am
Watchlist

Market Summary

USD9.62-0.10
Delayedas of 27 Sep 2023, 11:20 am
-1.03%

VTRS Stock Price

VTRS RSI Chart

VTRS Valuation

Market Cap

11.7B

Price/Earnings (Trailing)

6.3

Price/Sales (Trailing)

0.75

EV/EBITDA

1.8

Price/Free Cashflow

5.5

VTRS Price/Sales (Trailing)

VTRS Profitability

EBT Margin

16.51%

Return on Equity

9.1%

Return on Assets

3.86%

Free Cashflow Yield

18.18%

VTRS Fundamentals

VTRS Revenue

Revenue (TTM)

15.6B

Revenue Y/Y

-4.81%

Revenue Q/Q

5.08%

VTRS Earnings

Earnings (TTM)

1.9B

Earnings Y/Y

-15.9%

Earnings Q/Q

17.49%

Price Action

52 Week Range

8.3512.40
(Low)(High)

Last 7 days

-1.7%

Last 30 days

-11.4%

Trailing 12 Months

15.2%

VTRS Financial Health

Current Ratio

1.58

VTRS Investor Care

Dividend Yield

4.94%

Dividend/Share (TTM)

0.48

Buy Backs (1Y)

0.66%

Diluted EPS (TTM)

1.53

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs
Net sales

Latest Insider Trading transactions for VTRS

Filter Transactions
Datesorted ascendingNameBuy/Sell$ ValueAvg. Price# SharesTitle
2023-03-06
Ni Xiangyang (Sean)
sold
-34,890
11.0835
-3,148
president, greater china
2023-03-04
Narula Sanjeev
acquired
-
-
40,287
chief financial officer
2023-03-04
CORNWELL W DON
acquired
-
-
20,313
-
2023-03-04
GOETTLER MICHAEL
acquired
-
-
107,827
chief executive officer
2023-03-04
Mauro Anthony
acquired
-
-
37,917
see remarks
2023-03-04
van der Meer Mohr Pauline
acquired
-
-
20,313
-
2023-03-04
Cuneo Andrew
sold (taxes)
-32,188
11.13
-2,892
see remarks
2023-03-04
Campbell Paul
acquired
-
-
18,515
see remarks
2023-03-04
Cuneo Andrew
acquired
-
-
6,518
see remarks
2023-03-04
Narula Sanjeev
sold (taxes)
-194,964
11.13
-17,517
chief financial officer

1–10 of 50

Which funds bought or sold VTRS recently?

View All Details
Datesorted ascendingFund NameType% Chg$ Change$ Held% Portfolio
2023-09-21
Baystate Wealth Management LLC
added
3.44
863
12,614
-%
2023-09-20
BARCLAYS PLC
added
70.49
10,704,000
24,626,000
0.02%
2023-09-19
BIRMINGHAM CAPITAL MANAGEMENT CO INC/AL
reduced
-13.52
-77,830
678,735
0.28%
2023-09-13
CGC Financial Services, LLC
new
-
2,046
2,046
-%
2023-09-12
Farther Finance Advisors, LLC
added
21.59
9,424
45,469
0.01%
2023-09-08
TUCKER ASSET MANAGEMENT LLC
added
62.39
776
1,898
-%
2023-09-07
ST GERMAIN D J CO INC
new
-
56,437
56,437
-%
2023-09-05
Delos Wealth Advisors, LLC
added
0.76
60.00
1,321
-%
2023-08-28
DT Investment Partners, LLC
unchanged
-
928
11,028
-%
2023-08-24
Alberta Investment Management Corp
reduced
-97.75
-6,863,970
164,151
-%

1–10 of 48

Latest Funds Activity

Are funds buying VTRS calls or puts?
Calls
Puts
No. of funds holding Calls - Puts
Net Call Options
No. of funds that own VTRS
No. of Funds

Schedule 13G FIlings of Viatris

Date FiledName of FilerPercent of ClassNo. of SharesForm Type
Feb 09, 2023
vanguard group inc
12.31%
149,318,666
SC 13G/A
Feb 07, 2023
state street corp
5.10%
61,903,672
SC 13G
Jan 31, 2023
blackrock inc.
7.7%
93,214,306
SC 13G/A
Feb 04, 2022
wellington management group llp
4.57%
55,233,099
SC 13G/A
Feb 03, 2022
blackrock inc.
7.2%
86,554,658
SC 13G/A
Feb 04, 2021
wellington management group llp
5.74%
69,811,210
SC 13G
Feb 02, 2021
blackrock inc.
7.3%
89,526,414
SC 13G
Jan 08, 2021
vanguard group inc
10.62%
129,072,141
SC 13G

Recent SEC filings of Viatris

View All Filings
Date Filed Form Type Document
Aug 07, 2023
8-K
Current Report
Aug 07, 2023
10-Q
Quarterly Report

Peers (Alternatives to Viatris)

View All Peers In Detail
NameMkt Capsorted ascendingRevenuePrice %, 1MReturns, 1YP/EP/SRev 1-YrInc 1-Yr
LARGE-CAP
2.7T
383.9B
-3.72% 14.24%
28.4
7.01
-0.93% -4.89%
2.3T
211.9B
-3.36% 31.83%
32.06
10.95
6.88% -0.52%
1.6T
289.5B
-0.95% 31.01%
26.82
5.65
4.10% -15.36%
1.3T
538.0B
-5.46% 9.41%
99.39
2.41
10.73% 12.62%
MID-CAP
1.5B
9.9B
-27.56% -33.79%
54.14
0.15
24.14% 106.11%
766.5M
246.5M
-8.20% 4.63%
-4.82
3.11
6.65% -174.04%
SMALL-CAP
1.6B
627.1M
-7.75% -11.11%
-1.08
2.51
-0.20% -204.67%
1.5B
2.2B
-9.70% 14.84%
10.83
0.7
38.20% -10.10%
1.2B
56.2M
14.50% -61.04%
-1.37
20.54
40.31% -12.26%
1.0B
543.3M
-6.71% 14.01%
-692.78
1.85
31.74% 78.13%
602.7M
356.8M
-18.87% -35.56%
-2.14
1.69
-23.03% 15.53%
507.6M
453.3M
136.46% -66.34%
-0.41
1.12
-16.04% 55.90%
486.9M
1.0B
-15.55% -36.87%
-18.42
0.47
-11.34% -107.10%
99.4M
13.7M
-11.02% -77.34%
-0.59
7.28
413.65% 52.51%

Viatris News

Best Stocks
Analysts Recommend Holding onto HighYielding Health Care Stocks.
Best Stocks,
2 hours ago
The Pharma Letter
InvestorsObserver
InvestorsObserver
The Motley Fool
Zacks Investment Research

Returns for VTRS

Cumulative Returns on VTRS

-12.3%


10-Year Cumulative Returns

-17.9%


7-Year Cumulative Returns

-22.5%


5-Year Cumulative Returns

-10.4%


3-Year Cumulative Returns

Risks for VTRS

What is the probability of a big loss on VTRS?

100%


Probability that Viatris stock will be more than 20% underwater in next one year

71.5%


Probability that Viatris stock will be more than 30% underwater in next one year.

30%


Probability that Viatris stock will be more than 40% underwater in next one year.
*Calculated based on probability distribution of losses observed in actual data in the last 5 years.

How does VTRS drawdown profile look like?

Y-axis is the maximum loss one would have experienced if Viatris was unfortunately bought at previous high price.

Drawdowns

Financials for Viatris

Income Statement (Last 12 Months)
(In Millions)
Income Statement (Last 12 Months)
(In Millions)
(*) denotes actual numbers (not divided by Millions)
Description(%) Q/Q2023Q22023Q12022Q42022Q32022Q22022Q12021Q42021Q32021Q22021Q12020Q42020Q32020Q22020Q12019Q42018Q4
Revenue-1.3%15,60215,80016,26316,72817,18717,64817,88617,16815,60413,75711,94611,09710,70110,47711,50111,434
Gross Profit-1.5%6,1736,2686,4976,7696,5956,2195,5764,7364,3204,0183,7974,1203,8643,6243,8984,002
Operating Expenses1.7%5,0464,9614,8825,0315,0595,2805,6105,5735,1644,6804,0083,2272,1519623,1823,096
  S&GA Expenses1.2%4,2744,2234,1793,9974,0344,2584,5294,8084,4113,9263,3452,6442,6502,4222,5642,441
  R&D Expenses8.8%755694-747724709751639616625555534541457640705
EBITDA-100.0%-6,2236,4334,6424,7304,7384,4784,6603,5733,3231,9932,4422,1602,1402,6912,951
EBITDA Margin-100.0%-0.39*0.40*0.28*0.28*0.27*0.25*0.27*0.23*0.24*0.17*0.22*0.20*0.20*0.23*0.26*
Interest Expenses-0.4%591593592594592613636632598547498471472480517542
Earnings Before Taxes-2.2%2,5522,6082,8131,140913304-664-1,474-1,432-1,193-72139068.0041.00154298
EBT Margin-100.0%-0.17*0.17*0.07*0.05*0.02*-0.04*-0.06*-0.09*-0.05*-0.06*0.03*0.00*-0.01*0.03*
Net Income-2.6%1,8541,9042,079804761168-1,269-1,921-2,046-1,728-66932880.0028.0017.00353
Net Income Margin-100.0%-0.12*0.13*0.05*0.04*0.01*-0.07*-0.09*-0.13*-0.12*-0.06*-0.02*0.00*--0.03*
Free Cashflow-100.0%-2,3962,5472,8833,0832,8342,5603,3481,6761,540989-166718215-2132,090
Balance Sheet
(In Millions)
Balance Sheet
(In Millions)
(*) denotes actual numbers (not divided by Millions)
Description(%) Q/Q2023Q22023Q12022Q42022Q32022Q22022Q12021Q42021Q32021Q22021Q12020Q42020Q32020Q22019Q4
Assets-1.2%48,69549,29050,02248,66351,12553,46754,84356,07057,98458,97961,55311,41311,41231,256
  Current Assets1.5%9,7789,63010,63510,48811,17711,74410,90311,30811,75012,31912,86811,41311,4126,757
    Cash Equivalents24.2%6295071,260647665752706757674807844665324491
  Inventory-0.6%3,6423,6643,5203,3803,6133,7973,9784,0824,4884,9425,472--2,671
  Net PPE-0.8%2,9833,0083,0253,0393,0843,1503,1893,1143,1713,2473,460--2,150
  Goodwill-0.4%10,53310,57310,42610,05510,52310,97912,11412,17011,99011,90712,347--9,591
Liabilities-1.8%27,85228,36228,95029,48031,32033,01934,35034,92936,77737,56538,59911,61411,41319,372
  Current Liabilities6.8%6,5246,1086,7466,5217,6819,6439,88410,10410,1339,97810,56379.0028.005,569
  Short Term Borrowings-88.7%23.00205-5001,0206551,4931,7071,30137.001,100---
    LT Debt, Current162.3%1,3345091,2597647682,6061,8781,9082,1842,3002,309--1,508
    LT Debt, Non Current-4.6%17,24618,06918,01518,72519,20618,76319,71719,85420,91722,10222,42911,53511,38511,214
Shareholder's Equity-0.4%20,84320,92821,07219,18219,80520,44820,49321,14121,20721,41522,95412,54811,74611,884
  Retained Earnings2.2%5,3695,2535,1764,3134,1073,9423,6894,0873,9104,3245,361-170-0.906,031
  Additional Paid-In Capital0.2%18,71918,68018,64618,61718,58618,55518,53618,51418,49018,46518,439-31.00-0.308,644
Shares Outstanding-100.0%-1,203-1,2131,2121,211-1,2091,2091,208-517517-
Cashflow (Last 12 Months)
(In Millions)
Cashflow (Last 12 Months)
(In Millions)
(*) denotes actual numbers (not divided by Millions)
Description(%) Q/Q2023Q22023Q12022Q42022Q32022Q22022Q12021Q42021Q32021Q22021Q12020Q42020Q32020Q22020Q12019Q42019Q32019Q22018Q4
Cashflow From Operations-10.3%2,4982,7852,9533,3333,5503,3073,0172,5301,9691,7901,2321,5948943881,804--2,342
  Share Based Compensation7.5%14113111610910510711111810893.0079.0066.0069.0078.0057.00---3.30
Cashflow From Investing0.7%8438381,521-483-486-421-11779.0013981.00-301-371-293-194-525---1,210
Cashflow From Financing12.4%-3,367-3,843-3,877-2,896-3,015-2,921-3,012-2,513-1,781-1,680-605-1,006-812-33.07-1,169---1,090
  Dividend Payments--------532----------
  Buy Backs0%500500---------------432

VTRS Income Statement

2023-06-30
Condensed Consolidated Statements Of Operations - USD ($)
shares in Millions, $ in Millions
3 Months Ended6 Months Ended
Jun. 30, 2023
Jun. 30, 2022
Jun. 30, 2023
Jun. 30, 2022
Net sales$ 3,909.5$ 4,105.4$ 7,628.6$ 8,283.6
Total revenues3,918.64,116.87,647.78,308.5
Cost of sales2,310.02,413.54,496.94,834.0
Gross profit1,608.61,703.33,150.83,474.5
Operating expenses:    
Research and development208.3162.6391.2304.9
Payments to Acquire in Process Research and Development10.20.010.20.0
Selling, general and administrative1,031.9981.11,990.81,896.4
Litigation settlements and other contingencies, net(11.0)10.9(10.4)17.1
Total operating expenses1,239.41,154.62,381.82,218.4
Earnings from operations369.2548.7769.01,256.1
Interest expense143.7145.9290.7292.1
Other (income) expense, net(107.5)13.5(177.4)47.2
Earnings before income taxes333.0389.3655.7916.8
Income tax (benefit) provision69.075.4167.0203.7
Net earnings (loss)$ 264.0$ 313.9$ 488.7$ 713.1
Earnings per share attributable to Viatris Inc. shareholders    
Basic (in USD per share)$ 0.22$ 0.26$ 0.41$ 0.59
Diluted (in USD per share)$ 0.22$ 0.26$ 0.41$ 0.59
Weighted average shares outstanding:    
Basic 1,212.3 1,211.4
Diluted 1,217.1 1,215.1
Other Revenues    
Other revenues$ 9.1$ 11.4$ 19.1$ 24.9

VTRS Balance Sheet

2023-06-30
Condensed Consolidated Balance Sheets - USD ($)
$ in Millions
Jun. 30, 2023
Dec. 31, 2022
Current assets:  
Cash and cash equivalents$ 629.2$ 1,259.9
Accounts receivable, net3,607.33,814.5
Inventories3,641.53,519.5
Prepaid expenses and other current assets1,725.11,811.2
Assets held for sale174.9230.3
Total current assets9,778.010,635.4
Property, plant and equipment, net2,983.23,024.5
Intangible assets, net22,084.422,607.1
Goodwill10,532.510,425.8
Deferred income tax benefit966.0925.9
Other assets2,351.12,403.5
Total assets48,695.250,022.2
Current liabilities:  
Accounts payable1,962.01,766.6
Short-term borrowings23.20.0
Income taxes payable158.1279.6
Current portion of long-term debt and other long-term obligations1,334.41,259.1
Other current liabilities3,046.13,440.9
Total current liabilities6,523.86,746.2
Long-term debt17,246.018,015.2
Deferred income tax liability2,407.82,432.0
Other long-term obligations1,674.31,756.5
Total liabilities27,851.928,949.9
Viatris Inc. shareholders’ equity  
Common Stock, Value, Issued12.212.1
Additional paid-in capital18,719.418,645.8
Retained earnings5,369.15,175.6
Accumulated other comprehensive loss(3,005.6)(2,761.2)
Total Mylan N.V. equity, before treasury stock21,095.121,072.3
Total equity20,843.321,072.3
Total liabilities and equity$ 48,695.2$ 50,022.2
Michael Goettler
37000
Viatris Inc. operates as a healthcare company worldwide. The company operates in four segments: Developed Markets, Greater China, JANZ, and Emerging Markets. It offers prescription brand drugs, generic drugs, complex generic drugs, biosimilars, and active pharmaceutical ingredients (APIs). The company offers drugs in various therapeutic areas, including noncommunicable and infectious diseases; biosimilars in the areas of oncology, immunology, endocrinology, ophthalmology, and dermatology; and APIs for antibacterial, central nervous system agents, antihistamines/antiasthmatics, cardiovascular, antivirals, antidiabetics, antifungals, and proton pump inhibitor areas, as well as support services, such as diagnostic clinics, educational seminars, and digital tools to help patients better manage their health. It provides its medicines in the form of oral solid doses, injectables, complex dosage forms, and APIs to retail and pharmacy establishments, wholesalers and distributors, payers, insurers and governments, and institutions. The company distributes its products through pharmaceutical wholesalers/distributors, pharmaceutical retailers, institutional pharmacies, mail-order and e-commerce pharmacies, and specialty pharmacies. It sells its products under the Lyrica, Lipitor, Creon, Influvac, Wixela Inhub, EpiPen auto-injector, Fraxiparine, and Yupelri; Norvasc and Viagra; AMITIZA, Lipacreon, and Effexor; and Celebrex and ARV names, as well as offers biosimilars franchises, including Fulphila, Ogivri, Hulio, and SEMGLEE. The company has collaboration and licensing agreements with Revance Therapeutics, Inc.; Momenta Pharmaceuticals, Inc.; Theravance Biopharma, Inc.; Biocon Ltd.; and Fujifilm Kyowa Kirin Biologics Co. Ltd. Viatris Inc. was founded in 1961 and is headquartered in Canonsburg, Pennsylvania.